ISRCTN16538701 https://doi.org/10.1186/ISRCTN16538701

Combined treatment of heart failure after coronary heart disease

Submission date
15/05/2025

Recruitment status
No longer recruiting

Registration date
20/05/2025

Overall study status
Completed

Last Edited
19/05/2025

Condition category
Circulatory System

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[X] Record updated in last year

Plain English summary of protocol

Background and study aims
Qili cardiotonic capsule and Sacubitril/valsartan are commonly used drugs for the treatment of heart failure. The single drug treatment effect and prognosis are poor, and the combination of traditional Chinese and Western medicine can play the role of treating both symptoms and root causes. However, there are few studies on the combined treatment of heart failure at home and abroad. Therefore, this study took patients with heart failure after coronary heart disease as the research object, and explored the therapeutic effect of Qili cardiotonic capsule combined with Sacubitril/valsartan and its effect on NT-proBNP level.

Who can participate?
Patients with coronary heart disease and heart failure. The results showed that there were 33 males and 20 females in the experimental group, with an average age of 68.89 ± 10.60 years. There were 27 males and 23 females in the control group, with an average age of 68.30 ± 11.44 years.

What does the study involve?
The control group was treated with Sacubitril/valsartan orally, and the experimental group was treated with Sacubitril/valsartan combined with Qili cardiotonic capsule.

What are the possible benefits and risks of participating?
The combination of Sacubitril/valsartan and Qili cardiotonic capsule was more effective in the treatment of patients with coronary heart disease complicated with heart failureit can improve cardiac function in a short period of time.

Where is the study run from?
This study was conducted at Tianshui Hospital of Traditional Chinese Medicine (China)

When is the study starting and how long is it expected to run for?
This study was starting on October 1, 2022 and ending on April 1, 2025.

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Lan Hai , hanlan_lher@163.com

Contact information

Type(s)
Public, Scientific, Principal Investigator

Contact name
Ms Lan Hai

ORCID ID
http://orcid.org/0009-0004-7642-1378

Contact details
No.105 Jianshe Road
Tianshui City
China
741000
+86-18193837516
hanlan_lher@163.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
Nil known

Study information

Scientific Title
Clinical effect observation of Sacubitril/valsartan combined with Qili cardiotonic capsule on patients with heart failure after coronary heart disease

Acronym
CEOSVQLC

Study objectives
The combination of Sacubitril/valsartan and Qili cardiotonic capsule was more effective in the treatment of patients with coronary heart disease complicated with heart failure, and can improve cardiac function in the short term.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 10/04/2025, the Ethics Committee of Tianshui Traditional Chinese Medicine Hospital (Near the intersection of Nanming Road and Jiehe North Road in Zhongcheng Street, Tianshui City, 741000, China; +86-09388212475; mayupeng@21cn.com), ref: TSSZY2025-LY004-04

Study design
Single center randomized controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
No participant information sheet available

Health condition(s) or problem(s) studied
Combined treatment of heart failure after coronary heart disease

Interventions
106 patients with coronary heart disease and heart failure were randomly divided into control group and experimental group by simple random grouping method, 53 cases in each group.The control group was treated with Sacubitril/valsartan orally, and the experimental group was treated with Sacubitril/valsartan combined with Qili cardiotonic capsule. Both groups were followed up for 6 months.

Intervention Type
Drug

Pharmaceutical study type(s)
Pharmacodynamic

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Sacubitril/valsartan, Qili cardiotonic capsule

Primary outcome measure

1. N-terminal pro-brain natriuretic peptide (NT-proBNP) is measured using immunoassay at baseline and at 6 months
2. 6-minute walking distance is measured using the 6-minute walking test (6MWT) at baseline and at 6 months
3. Left ventricular ejection fraction (LVEF) is measured using echocardiography at baseline and at 6 months
4. Left ventricular end-systolic diameter (LVESD) is measured using echocardiography at baseline and at 6 months
5. Left ventricular end-diastolic diameter (LVEDD) is measured using echocardiography at baseline and at 6 months

Secondary outcome measures
There are no secondary outcome measures

Overall study start date
01/10/2022

Completion date
01/04/2025

Eligibility

Key inclusion criteria
1. Meeting the 2021 European Society of Cardiology diagnostic criteria and treatment guidelines for acute and chronic heart failure;
2. The heart failure classification conformed to the New York Heart Association (NYHA) cardiac function classification II-IV;
3. Chronic heart failure with coronary heart disease.

Participant type(s)
Patient

Age group
Adult

Lower age limit
55 Years

Upper age limit
80 Years

Sex
Both

Target number of participants
106

Total final enrolment
106

Key exclusion criteria
1. Combined with other cardiovascular diseases leading to heart failure, such as severe valvular disease, malignant arrhythmia, acute myocarditis, acute myocardial infarction, various types of cardiomyopathy, malignant hypertension
2. Complicated with severe liver, kidney, lung or other important organ dysfunction
3. Combined with malignant tumor; severe anemia requiring blood transfusion
4. Patients who could not complete all follow-ups
5. Patients who did not test blood routine within 24 hours of hospitalization

Date of first enrolment
01/12/2022

Date of final enrolment
31/08/2024

Locations

Countries of recruitment
China

Study participating centre
Tianshui Hospital of Traditional Chinese Medicine
Near the intersection of Nanming Road and Jiehe North Road in Zhongcheng Street
Tianshui City
China
741000

Sponsor information

Organisation
Tianshui Hospital of Traditional Chinese Medicine

Sponsor details
Near the intersection of Nanming Road and Jiehe North Road in Zhongcheng Street
Tianshui City
China
741000
+86-09388212475
mayupeng@21cn.com

Sponsor type
Hospital/treatment centre

Website
https://tszyyy.cn/

Funder(s)

Funder type
Other

Funder Name
Investigator initiated and funded

Results and Publications

Publication and dissemination plan
Planner publication in a peer-reviewed journal.

Intention to publish date
30/05/2026

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
hanlan_lher@163.com

IPD sharing plan summary
Available on request